Moderna (NASDAQ:MRNA) Cut to Equal Weight at Barclays
Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, MarketBeat Ratings reports. The firm currently has $45.00 price target on the stock, down from their previous price target of $111.00. MRNA has been the topic of several other reports. The […]
Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, MarketBeat Ratings reports. The firm currently has $45.00 price target on the stock, down from their previous price target of $111.00. MRNA has been the topic of several other reports. The […]
